Clinical Trial Update: Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis [Phase 2]

View source ↗

Summary

Phase 2 trial results update evaluating everolimus (RAD001) as therapy for patients with systemic mastocytosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Mastocytosis

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Systemic Mastocytosis | Phase 2 | Status: COMPLETED | Results posted: 2011-04-29